Table 1 Socio‑demographic and clinical characteristics of the sample (N = 64)
From: Methylomic biomarkers of lithium response in bipolar disorder: a clinical utility study
PaR + GR n = 44 | NR N = 20 | p* | |
|---|---|---|---|
N (%) or median (IQR) | N (%) or median (IQR) | ||
Socio-demographics | |||
Age at inclusion | 42 (32–50) | 43 (32–49) | 0.91 |
Sex (females) | 24 (54%) | 11 (55%) | 0.97 |
Family history | |||
First-degrees relatives with BD | 21 (48%) | 5 (25%) | 0.09 |
Mode of onset | |||
Age at BD onset | 23 (18–31) | 25 (18–32) | 0.83 |
Psychotic symptoms at onset | 11 (25%) | 7 (35%) | 0.41 |
Manic polarity at onset | 22 (50%) | 5 (25%) | 0.06 |
BD Course | |||
Rapid cycling | 6 (14%) | 1 (5%) | 0.42 |
Duration of the illness | 16 (9–24) | 14 (8–20) | 0.45 |
Lifetime number of episodes | 8 (5–10) | 8.5 (5–11) | 0.49 |
Lifetime number of hospitalizations | 4 (2–6) | 4 (3–7) | 0.26 |
Lithium as first prescribed stabilizer | 27 (61%) | 10 (50%) | 0.42 |
Comorbidities | |||
Current tobacco use | 26 (59%) | 12 (60%) | 0.94 |
Lifetime alcohol misuse | 9 (20%) | 4 (20%) | 0.62 |
Lifetime cannabis misuse | 4 (9%) | 5 (25%) | 0.09 |
Lifetime panic disorders | 6 (14%) | 4 (20%) | 0.54 |